Highly Sensitive and Specific Multiplex Antibody Assays To Quantify Immunoglobulins M, A, and G against SARS-CoV-2 Antigens
暂无分享,去创建一个
P. Santamaria | G. Moncunill | C. Dobaño | A. Jiménez | A. Mayor | L. Izquierdo | R. Santano | M. Vidal | R. Aguilar | P. Serra | C. Carolis | J. Chi | D. Barrios | F. Carmona-Torre | G. Reina | D. Parras | N. Rodrigo Melero | Gemma Ruiz-Olalla | A. García-Basteiro | Paula Martínez de Aguirre | Francisco Carmona-Torre
[1] L. Schroeder,et al. Differences in Performance Characteristics Among Four High-Throughput Assays for the Detection of Antibodies Against SARS-CoV-2 Using a Common Set of Patient Samples , 2020, American journal of clinical pathology.
[2] A. Rabello,et al. Diagnostic performance of commercially available COVID-19 serology tests in Brazil , 2020, International Journal of Infectious Diseases.
[3] Melis N. Anahtar,et al. Evaluation of Three Commercial SARS-CoV-2 Serologic Assays and Their Performance in Two-Test Algorithms , 2020, Journal of Clinical Microbiology.
[4] N. Hacohen,et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity , 2020, Science.
[5] G. Rodger,et al. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison , 2020, The Lancet Infectious Diseases.
[6] M. Rodgers,et al. A comparative evaluation between the Abbott Panbio™ COVID-19 IgG/IgM rapid test device and Abbott Architect™ SARS CoV-2 IgG assay , 2020, Journal of Clinical Virology.
[7] M. Koopmans,et al. SARS-CoV-2–Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence , 2020, medRxiv.
[8] L. Guddat,et al. Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase , 2020, Cell.
[9] J. Greenbaum,et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.
[10] Gagan Mathur,et al. Antibody Testing For Covid-19 , 2020, American journal of clinical pathology.
[11] P. Whiting,et al. Interpreting a covid-19 test result , 2020, BMJ.
[12] A. Meola,et al. Serological signatures of SARS-CoV-2 infection: Implications for antibody-based diagnostics , 2020, medRxiv.
[13] J. Hecht,et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital , 2020, Nature Communications.
[14] O. Tsang,et al. Beyond the Spike: identification of viral targets of the antibody response to SARS-CoV-2 in COVID-19 patients , 2020, medRxiv.
[15] Lei Liu,et al. Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] Daniel M Altmann,et al. What policy makers need to know about COVID-19 protective immunity , 2020, The Lancet.
[17] R. Davey,et al. Detection of Nucleocapsid Antibody to SARS-CoV-2 is More Sensitive than Antibody to Spike Protein in COVID-19 Patients , 2020, medRxiv.
[18] C. Hillyer,et al. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses , 2020, Trends in Immunology.
[19] U. Reimer,et al. Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors , 2020, medRxiv.
[20] S. Hegde,et al. The important role of serology for COVID-19 control , 2020, The Lancet Infectious Diseases.
[21] Yan-ling Ma,et al. Antibody Detection and Dynamic Characteristics in Patients with COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] Michael Libman,et al. Diagnostic Testing for Severe Acute Respiratory Syndrome–Related Coronavirus-2 , 2020, Annals of Internal Medicine.
[23] K. Yuen,et al. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2 , 2020, Cell.
[24] C. Hillyer,et al. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses , 2020, Trends in Immunology.
[25] M. Day. Covid-19: four fifths of cases are asymptomatic, China figures indicate , 2020, BMJ.
[26] The Cell Editorial Team. Embracing the Landscape of Therapeutics , 2020, Cell.
[27] C. Whittaker,et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis , 2020, The Lancet Infectious Diseases.
[28] A. Buisman,et al. Immune surveillance for vaccine-preventable diseases , 2020, Expert review of vaccines.
[29] P. Felgner,et al. Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray , 2020, bioRxiv.
[30] O. Tsang,et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study , 2020, The Lancet Infectious Diseases.
[31] S. Zhang,et al. The index case of SARS-CoV-2 in Scotland , 2020, Journal of Infection.
[32] Qi Jin,et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[33] Y. Yazdanpanah,et al. SARS-CoV-2 specific antibody responses in COVID-19 patients , 2020, medRxiv.
[34] Pu Liao,et al. Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice , 2020, medRxiv.
[35] Philip L. Felgner,et al. A serological assay to detect SARS-CoV-2 seroconversion in humans , 2020, medRxiv.
[36] Chuan Qin,et al. Reinfection could not occur in SARS-CoV-2 infected rhesus macaques , 2020 .
[37] H. Gao,et al. Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2 , 2020, bioRxiv.
[38] Lei Liu,et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 , 2020, medRxiv.
[39] G. Gao,et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.
[40] J. Hepojoki,et al. Immunoassay for serodiagnosis of Zika virus infection based on time-resolved Förster resonance energy transfer , 2019, PloS one.
[41] Y. Dong,et al. Analysis of factors affecting the variability of a quantitative suspension bead array assay measuring IgG to multiple Plasmodium antigens , 2018, PloS one.
[42] Virander S. Chauhan,et al. Optimization of incubation conditions of Plasmodium falciparum antibody multiplex assays to measure IgG, IgG1–4, IgM and IgE using standard and customized reference pools for sero-epidemiological and vaccine studies , 2018, Malaria Journal.
[43] J. Campo,et al. Development of a high-throughput flexible quantitative suspension array assay for IgG against multiple Plasmodium falciparum antigens , 2018, Malaria Journal.
[44] Joseph J Campo,et al. Development of quantitative suspension array assays for six immunoglobulin isotypes and subclasses to multiple Plasmodium falciparum antigens. , 2018, Journal of immunological methods.
[45] N. Bizzaro,et al. Chemiluminescent immunoassay technology: what does it change in autoantibody detection? , 2017, Autoimmunity Highlights.
[46] K. M. Koczula,et al. Lateral flow assays , 2016, Essays in biochemistry.
[47] Christian Drosten,et al. Serological assays for emerging coronaviruses: Challenges and pitfalls , 2014, Virus Research.
[48] Xavier Robin,et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.
[49] Yan J. Zhang,et al. Characterization and development of a Luminex(®)-based assay for the detection of human IL-23. , 2010, Bioanalysis.
[50] F. Plummer,et al. Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology , 2010, mAbs.
[51] J. Mendoza,et al. Development of an Enzyme-Linked Immunosorbent Assay-Based Test with a Cocktail of Nucleocapsid and Spike Proteins for Detection of Severe Acute Respiratory Syndrome-Associated Coronavirus-Specific Antibody , 2008, Clinical and Vaccine Immunology.
[52] Wei Liu,et al. Two-Year Prospective Study of the Humoral Immune Response of Patients with Severe Acute Respiratory Syndrome , 2006, The Journal of infectious diseases.
[53] Haiyan Wei,et al. Profiles of IgG antibodies to nucleocapsid and spike proteins of the SARS-associated coronavirus in SARS patients. , 2005, DNA and cell biology.
[54] Arul Earnest,et al. Asymptomatic SARS Coronavirus Infection among Healthcare Workers, Singapore , 2005, Emerging infectious diseases.
[55] V. Cheng,et al. Antigenic Cross-Reactivity between Severe Acute Respiratory Syndrome—Associated Coronavirus and Human Coronaviruses 229E and OC43 , 2005, The Journal of infectious diseases.
[56] Runsheng Chen,et al. Antibody responses to individual proteins of SARS coronavirus and their neutralization activities , 2005, Microbes and Infection.
[57] G. Tang,et al. Indian Hedgehog: A Mechanotransduction Mediator in Condylar Cartilage , 2004, Journal of dental research.
[58] D. Vignali,et al. Simultaneous quantitation of 15 cytokines using a multiplexed flow cytometric assay. , 1999, Journal of immunological methods.
[59] D. Tyrrell,et al. The time course of the immune response to experimental coronavirus infection of man , 1990, Epidemiology and Infection.
[60] E. Engvall,et al. Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. , 1971, Immunochemistry.
[61] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[62] Andy Liaw,et al. Classification and Regression by randomForest , 2007 .
[63] Dr Ferdiye Taner,et al. The enzyme-linked immunosorbent assay (ELISA). , 1976, Bulletin of the World Health Organization.